Michael D. Hooven
President and CEO
Mike Hooven has over 30 years of experience in the medical device industry in a broad variety of technical and clinical areas. He is the founder of three medical device companies and holds over 100 issued and pending US patents.
Mike is the founder, and a Director of AtriCure, Inc. (Nasdaq ATRC). AtriCure is a Medical Device company that manufactures and sells surgical devices to treat the most serious forms of atrial fibrillation. AtriCure has grown rapidly to become the market leader, with over 200,000 procedures performed. AtriCure completed a successful Initial Public Offering on August 5, 2005, and currently lists on the NASDAQ under the symbol ATRC as a multibillion-dollar company. Mike also is a Director and past Chairman of BioOhio, a state-funded organization to accelerate life-science start-up companies in Ohio. Mike was appointed by the Governor to the Third Frontier Advisory Board, a $2.3BB state funded initiative to accelerate high tech job creation in Ohio. Mike also sits on the Commercial Advisory Committee for the University of Cincinnati.
Mike previously held positions as the Chairman and CEO of AtriCure, and the Founder and Chairman of Enable Medical, a surgical device manufacturer that was acquired by AtriCure in August of 2005. Mike founded Enable in April of 1994, and prior to that he headed up all internal product development at Ethicon Endo-Surgery from 1988 to 1994. Mike held Engineering positions at Siemens/Pacesetter from 1986 to 1988, and at Cordis Corporation from 1981 to 1986. He earned a BS in Physics and a Master of Science in Mechanical Engineering from the University of Michigan.
Executive Vice President and Chief Financial Officer
Tim Flaherty has more than 25 years of public and private company experience in finance, accounting, human resource, and information technology management. At Enable Injections, he is responsible for the finance, accounting, and information technology. Prior to Enable Injections, Tim served as North American CFO for Bonfiglioli, Inc., a leading billion-dollar global Italian owned company in the power transmission market. Tim was nominated for CFO of the year in 2014 by the Cincinnati Business Courier in the large private company category for his achievements at Bonfiglioli, Inc.
Prior to Bonfiglioli, Tim held several executive financial roles in large publicly traded companies and small private companies, including ArvinMeritor (NYSE:ARM), Ametek (NYSE:AME), and AtriCure /Enable Medical (NASD: ATRC), with experience in Merger and Acquisitions, IPO experience, plant consolidations, shared-service operations, multi-location oversight, SEC Reporting, system implementations, scalability, cost and risk controls, and forecasting and strategy. Tim earned his accounting degree from the University of Kentucky and his Master of Business Administration from Xavier University, Cincinnati, OH.
Matthew J. Huddleston
Executive Vice President, Business Development, and Chief Technology Officer
Mr. Matthew J. Huddleston serves as Executive Vice President and Chief Technology Officer for Enable Injections. He is an experienced medical device professional with more than 20 years of experience in startup environments with emphasis in project management, design, development, manufacturing, regulatory, and intellectual property. He has several issued and pending patents in the medical device field, including soft tissue and cardiovascular fixation devices and delivery instruments, histologic automated embedding systems, laparoscopic visualization devices, and automatic injection devices. He is a professional engineer and a licensed patent agent. Matt holds a Bachelor of Science in Mechanical Engineering from Purdue University and a Master of Science in Biomedical Engineering from The Ohio State University.
Senior Vice President, Human Resources and Strategic Growth
Tiffany Khodadad has over 20 years of pharmaceutical experience in operations, regulatory affairs, human resources, and strategic planning and change management. Tiffany joined Enable in 2016 and has been instrumental in its growth. Prior to joining Enable, Tiffany formerly worked with Cincinnati Children’s Hospital Medical Center, Medpace, a global CRO, and a niche pharmaceutical company. Tiffany earned her bachelor’s at The Ohio State University and master’s at New York University.
Executive Vice President and Chief Operating Officer
Donald Kirkpatrick has over 30 years of experience in healthcare operations and product development. At Enable Injections, he is responsible for Product Development and Operations for the enFuse on-body platform. He joined Enable from Baxter Healthcare, where he was most recently the Head of External Contract Manufacturing, responsible for global leadership of external finished product manufacturing of electromechanical, disposable, pharmaceutical, and biologic products. Don previously served as Director, Operations Strategy where he led Operations strategy development for global plastics processes across the Baxter manufacturing plant network, as well as operations strategy and diligence for Mergers & Acquisitions, outsourcing and third-party manufacturing.
Prior to Baxter, Don held various senior positions in the medical device and IVD industry at Haemonetics, Teleflex Medical, and Arrow International, including manufacturing operations positions in the US, China, and Japan. Don earned a Bachelor of Science in Mechanical Engineering Technology from the University of Massachusetts and a Master of Business Administration from Boston College.
Executive Biotech Advisor
Don Rindell has more than 30 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development, and device & diagnostic technology strategy for several US and European pharmaceutical and medical device companies.
Mr. Rindell is currently Managing Director of Camino International, LLC, a consulting practice for Business and Product Development. He is currently managing several partnered pharmacodiagnostic programs for Bristol Myers Squibb’s Translational Medicine initiatives in oncology. He previously served as Senior Director of Corporate Development at Amylin Pharmaceuticals, which was purchased by Bristol Myers Squibb. At Amylin, he led a number of key global transactions with companies including Shionogi Pharmaceuticals, Biocon, Takeda Pharmaceuticals and selected device delivery companies. He also provided management leadership to the Amylin Drug Delivery Team. He has previously held senior executive positions at CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, Hybritech, and Syntex.
Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.
Senior Vice President, Program General Manager
Eileen has more than 25 years of experience in the life sciences industry. A majority of her career has focused on biopharmaceutical manufacturing of sterile products in compliance with the FDA’s Code of Federal Regulations as well as ISO and ICH guidelines to meet global regulatory needs. Eileen filled various management roles in Validation, Engineering and Capital Expansion while working for both Stryker Biotech and Amylin Pharmaceuticals. As the Senior Director of Operations at Amylin, Eileen led a cross functional team in the development and approval of an innovative drug delivery system for a sterile injectable product. Currently, Eileen is the Vice President of Program Management and Human Factors at Enable Injections championing device and instructional design with a focus on user needs, usability requirements and minimizing use errors. Eileen also serves as the key liaison for drug partnerships throughout the life cycle of the collaboration, oversees the integration and progress of major milestones in various project teams and ensures communication with all stakeholders. Eileen received her Bachelor of Science degree in Civil Engineering from Drexel University and a Masters degree in Engineering Management from the Thayer School of Engineering at Dartmouth College.
Dominick C. Villani III
Senior Vice President, Quality / Regulatory Affairs
Dominick Villani has more than 20 years of experience in the Biotechnology, Vaccine, Pharmaceuticals (Sterile and Non-Sterile), and Medical Device sector, responsible for defining, building, and managing requirements within Manufacturing, Quality Control, Quality Assurance, and Regulatory Affairs with multiple companies, including Amgen, Amylin, AstraZeneca, Bristol-Myers Squibb, and Bioport. Dominick joined Enable Injections in 2016 and is a member of the International Organization for Standardization (ISO) for needle-based injections systems and on-body delivery systems. Dominick studied general Biological Sciences, with an emphasis in Microbiology, at the California Lutheran University in Thousand Oaks, California.